Top 5 Warren Buffett Stocks To Watch For 2015


Bloomberg News

The idea of a “great rotation” from bonds to stocks is flawed and investors expecting that shift to boost equity prices may be disappointed, according to Sanford C. Bernstein & Co.

“A rotation mental model may stem from incomplete notions of supply, demand, pricing and flows in capital markets,” Luke Montgomery, an analyst at the New York-based firm covering asset managers, wrote Friday in a note to clients.

Montgomery cited misconceptions over what happens when one investment type appears to win favor at the expense of another, saying there’s no automatic correlation between the migration of money and asset prices. He also disputed the notion that individual investors are holding less in stocks than they have historically, supposedly setting up a major shift.

Top 5 Warren Buffett Stocks To Watch For 2015: Affymax Inc.(AFFY)


Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to develop and commercialize Hematide. Affymax, Inc. was founded in 2001 and is based in Palo Alto, California.


Advisors’ Opinion:

  • [By Alpha Exposure]

    Investors in Affymax (AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the future for Omontys is in fact dire. At the conclusion of this article all doubt should be removed regarding the low likelihood that Omontys returns to market.

  • [By Kanak Kanti De]

    Amgen needed an Onyx-like acquisition badly. For one, sales of Aranesp and Epogen, its flagship drugs for anemia, are dropping on concerns of safety, and loss of monopoly in 2012 to Affymax (AFFY), which received FDA approval for a rival anemia drug. (Note though, that after Omontys was recalled this year, that problem is resolved for Amgen.) Secondly, four of its top selling products go off patent in 2015.

Top 5 Warren Buffett Stocks To Watch For 2015: Neutra Corp (NTRR)


Neutra Corp. incorporated on January 11, 2011, is a development-stage company. The Company’s business and registered office is located in Sarasota, Florida. The Company’s intended private label products consists of aging, cognitive support, antioxidants/flavonoids, circulatory support, detoxification support, endocrine support, essential fatty acids, gastrointestinal support, immune support, men’s health, minerals, mood/sleep support, multiples, musculoskeletal support, neurological support, proteins/amino acids, vitamins, women’s health and veterinary products. The Company’s product focuses to research and development in a range of areas, such as weight-loss, detox, men’s health, acid-alkali pH balance, anti-aging, sleep disorders, autism, pain management with the use of medical cannabis products, and air space sanitation derived by nutraceutical technology.


The Company focuses to market and sell nutraceutical supplement products to health practi tioners. It focuses direct marketing and sales towards Members of the American Association for Health Freedom (American Association for Health Freedom has merged with Alliance for Natural Health) www.anh-usa.org; American Association of Naturopathic Physicians, www.naturopathic.org; American Association of Oriental Medicine, www.aaom.org, and American College for Advancement in Medicine, www.acamnet.org. It also focuses direct marketing and sales towards American Holistic Medical Association, www.holisticmedicine.org; American Dietetic Association, www.eatright.org, and American Herbalist Guild, www.americanherbalistsguild.com.


The Company competes with Thone Research, The Vitamin Company, Nutraceutical International Corporation, Protocol For Life, Medagenics and Standard Process.

Advisors’ Opinion:

  • [By CRWE]

    Today, NTRR surged (+19.45%) up +0.068 at $.420 with 22,114 shares in play thus far (ref. google finance Delayed: 11:17AM EDT July 11, 2013).

    As Neutra Corp. works to deliver new innovations to the U.S. medical marijuana industry, the market for those innovations continues to grow. Last week, lawmakers passed a bill to make New Hampshire the 19th state to approve medical marijuana (MMJ) prescriptions for patients with chronic or terminal illnesses.


    The legislation will make New Hampshire the 19th state to legalize MMJ, in addition to the District of Columbia. Five more states have legislation pending to legalize prescriptions, according to ProCon.org.

  • [By CRWE]

    Today, NTRR has shed (-5.26%) down -0.020 at $.360 with 14,150 shares in play thus far (ref. google finance Delayed: 10:46AM EDT July 3, 2013), but don’t let this get you down.

    Neutra Corp. through a key new partnership with an innovative cannabis delivery systems provider in the medical marijuana industry, is poised to make an impact in the lucrative $52 billion pain management market.


    With partner Field of View Technologies, LLC, exploring new technology in cannabis delivery systems, NTRR is ready to provide much-needed smokeless delivery systems to those most in need: patients forced to live with debilitating pain.

    A recent study by Columbia University found that smoke-free cannabinoid medication was effective in treating pain. Smokeless delivery systems can be administered orally, by injection or topically, giving the patient the choice of treatment method as NTRR and Field of View set the pace in the potentially lucrative pain management market.

Top 5 Warren Buffett Stocks To Watch For 2015: STR Holdings Inc(STRI)


STR Holdings, Inc., together with its subsidiaries, designs, develops, manufactures, and sells encapsulants for the solar industry worldwide. Its encapsulants protect the embedded semiconductor circuits of solar panels. The company sells its products to crystalline silicon and thin-film solar module manufacturers. STR Holdings, Inc. was founded in 1944 and is headquartered in Enfield, Connecticut.

Advisors’ Opinion:

  • [By John Udovich]

    Solar stocks have not exactly given buy and hold investors a smooth ride, but small cap GT Advanced Technologies Inc (NASDAQ: GTAT) could be an interesting materials play on the solar sector – meaning its worth taking a closer look at the stock along with potential peers like Ascent Solar Technologies, Inc (NASDAQ: ASTI) and STR Holdings, Inc (NYSE: STRI) plus solar ETF Guggenheim Solar ETF (NYSEARCA: TAN). I should mention that just last week, we added GT Advanced Technologies to our SmallCap Network Elite Opportunity (SCN EO) portfolio for both fundamentals and technical reasons and we are already up almost 9%.

Top 5 Warren Buffett Stocks To Watch For 2015: CareFusion Corp (CFN)


CareFusion Corporation (CareFusion), incorporated on January 14, 2009, is a global medical technology company. The Company operates in two segments: Medical Systems and Procedural Solutions. The Medical Systems segment is organized around its medical equipment businesses. The Company’s Medical Systems segment’s business units and product lines include Infusion Systems, Dispensing Technologies, and Respiratory Technologies. The Procedural Solutions segment is organized around the Company’s disposable products and reusable surgical instruments businesses. The Company’s Procedural Solutions segment’s business units and product lines include Infection Prevention, Medical Specialties and Specialty Disposables. In August 2011, the Company acquired Rowa. In June 2012, the Company acquired U.K. Medical Limited. In July 2012, Natus Medical, Inc. acquired the Nicolet neurodiagnostic business from CareFusion. Effective December 31, 2013, CareFusion Corp acquired Vital Signs Inc from GE Healthcare, a unit of General Electric Co.


Medical Systems Segment

The Company’s develops, manufactures and markets capital equipment and related supplies for medication management, which includes its infusion and medication dispensing technologies, supply dispensing technologies and respiratory technologies. Its products are designed to enable healthcare professionals to improve patient safety by reducing medication errors and improving administrative controls, while simultaneously improving workflow and increasing operational efficiency. The Company sells these products primarily through its direct sales force, but use third-party distributors as well, particularly outside the United States. Many of its products in this segment are integrated with other information systems within the hospital, including financial and business systems that support patient admissions, discharges and transfers, operational systems that include invento ry management and clinical systems that include pharmacy inf! ormation and electronic medical records.


The Company offers value-added services and programs, software technical services and clinical education, which are designed to enhance its customers’ utilization of its medical equipment products. The Company’s project management, field service organization and customer call centers support its customers before, during and after product installation. The Company’s project management teams assist customers with the development of project implementation plans, which are designed to ensure rapid, seamless implementation of its products. The Company’s field service organization provides on-site expertise to resolve customers’ service issues. The Company’s customer call centers provide additional support to its customers.


The Company is engaged in designing, developing and marketing of IV infusion systems that deliver medications and other fluids directly into a patient’s veins in precise, measured quantities over a range of infusion rates. The Company is provider of point-of-care systems that automate the dispensing of medications and supplies in hospitals and other healthcare facilities in the United States. The Company develops, manufactures, markets and services mechanical ventilators and associated consumables for patients with respiratory disorders.

The Company competes with Baxter International, B. Braun, Fresenius Kabi, Hospira, Omnicell, McKesson; Drager, and MAQUET.


Procedural Solutions Segment

The Procedural Solutions segment is organized around its disposable products and reusable surgical instruments businesses. In its Procedural Solutions segment, the Company develops, manufactures and markets single-use skin antiseptic and other patient-preparation products, non-dedicated IV infusion administration sets and accessories, reusable surgical instruments and non-dedicated ventilator circuits and other disposables used for providing respiratory therapy. The products in this segm! ent are u! sed in the operating room, interventional suites, and in the critical care departments of hospitals. The Company sells these products and services through a combination of direct sales representatives and third-party distributors.


The Company’s Infection Prevention business unit consists mainly of single-use medical products used in surgical and vascular access procedures, including skin preparation products and disposable IV infusion administration sets and accessories. The Company’s Medical Specialties business unit consists mainly of specialty medical devices used in delivering interventional care and reusable surgical instrumentation products. The Company’s Specialty Disposables business unit focuses on providing clinicians with respiratory consumable products that work either independently or in conjunction with its range of ventilators.


The Company competes with 3M, ICU Medical, Becton, Dickinson, Baxter International, B. Braun; Hospira; Smiths Medical; CR Bard, Integra Life Sciences, and Teleflex.

Advisors’ Opinion:

  • [By Alanna Petroff]

    Medical technology firm Becton, Dickinson and Co (BDX) is taking over CareFusion (CFN) in a cash and stock deal that values CareFusion shares at $58 each.

  • [By ovenerio]

    In the medical supplies division (17%), Covidien competes with Becton Dickinson (BDX), 3M (MMM), Con- Med, CareFusion (CFN) and First Quality.


    Strengths

  • [By John Udovich]

    Overlooked mid cap medical technology and systems stock CareFusion Corporation (NYSE: CFN) could offer nice growth in the healthcare space, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like the iShares Dow Jones US Medical Device ETF (NYSEARCA: IHI) and SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE). I should mention that we have recently added CareFusion Corporation to our SmallCap Network Elite Opportunity (SCN EO) portfolio because the stock continues to be in a long-term thrusting patter and we believe its also undervalued based on current valuation.

Top 5 Warren Buffett Stocks To Watch For 2015: Trina Solar Limited(TSL)


Trina Solar Limited, through its subsidiaries, designs, develops, manufactures, and sells photovoltaic (PV) modules worldwide. The company offers monocrystalline PV modules ranging from 165 watts to 185 watts in power output; and multicrystalline PV modules ranging from 215 watts to 240 watts in power output that provide electric power for residential, commercial, industrial, and other applications. It also involves in the design and production of various PV modules, such as colored modules for architectural applications and larger sized modules for utility grid applications based on customers? and end-users? specifications. Trina Solar Limited sells and markets its products primarily to distributors, wholesalers, power plant developers and operators, and PV system integrators. The company was founded in 1997 and is based in Changzhou, the People?s Republic of China.


Advisors’ Opinion:

  • [By Roberto Pedone]

    Another potential earnings short-squeeze candidate is integrated solar-power products maker Trina Solar (TSL), which is set to release numbers on next Monday before the market open. Wall Street analysts, on average, expect Trina Solar to report revenue of $645.68 million on earnings of 15 cents per share.

    The current short interest as a percentage of the float for Trina Solar is extremely high at 24.5%. That means that out of the 76.94 million shares in the tradable float, 18.88 million shares are sold short by the bears. If the bulls get the earnings news they’re looking for, then shares of TSL could easily rip sharply higher post-earnings as the bears move to cover some of their positions.

    From a technical perspective, TSL is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock recently formed a double bottom chart pattern at $8.67 to $9.04 a share. Shares of TSL have now started to rebound off those support levels and it’s quickly moving within range of triggering a major breakout trade post-earnings above some key near-term overhead resistance levels.

    If you’re bullish on TSL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $10.72 to $11.19 a share and then above its 50-day moving average of $11.17 a share with high volume. Look for volume on that move that hits near or above its three-month average action of 5.17 million shares. If that breakout materializes post-earnings, then TSL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $12.49 to $14 a share, or even $14.50 to $15 a share.

    I would avoid TSL or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below some near-term support levels at $10 a share to those double bottom support levels at $9.04 to $8

  • [By Maria Armental var popups = dojo.query(“.socialByline .popC”); popups.forEach]

    Yingli Green said it will continue to fight a U.S. plan to close a loophole that allowed Chinese solar manufacturers to avoid tariffs by assembling their products outside China. Yingli shares dropped 6.4% to $2.76 premarket. Among the other Chinese solar stocks trading lower Wednesday are JinkoSolar Holding Co.(JKS), Trina Solar Ltd.(TSL) and JA Solar Holdings Co.(JASO)